Combination therapy for augmenting the anti-cancer drug 5-FU (5-Flurouracil) sensitivity in Human cancers: 15-deoxy-delta(12,14)-prostaglandin J2 (PGJ2) decreases the expression of the rate-limiting enzyme of the ‘uracil catabolic pathway’ Dihydropyrimidine dehydrogenase (DPYD), increases 5-FU accumulation in cancer cells, augments chemosensitivity, and anti-tumor effect via upregulation of its target gene, 24/January/2017, 11.01 pm

Anticancer therapy targeting the cancer stem cells: MiRNA-9600 inhibits the expression of stem cell gene/reprogramming protein Nanog, suppresses proliferation, and promotes apoptosis of cancer cells via down regulation of its target gene, 24/January/2016, 10.53 pm
February 24, 2017
Natural product-derived PD-L1 pathway blockade enhances the efficacy of Cancer immunotherapy: Bergapten, isolated from Bergamot, inhibits the expression of PD-L1, inhibits inflammatory signalling and the number of tumor-infiltrating lymphocytes and macrophages, increases Cytotoxic activity of T-cells, decreases tumor burden and increases survival via up-regulation of its target gene, 24/February/2017, 11.27 pm
February 24, 2017
Show all

From Research findings to Therapeutic opportunity: 

The study presented here suggests that 15-deoxy-delta(12,14)-prostaglandin J2 (PGJ2), by increasing the expression of its target genes, it may: (i) decrease the expression of Dihydropyrimidine dehydrogenase (DPYD); (ii) increase 5-FU accumulation in cancer cells; (iii) augment and restore chemosensitivity in drug-resistant Human cancers; (iv) promote anti-tumor effect; and (v) enhance the efficacy of anticancer drug treatment.

price-5

[easy_payment currency=”USD”]

Thereby, it may inhibit proliferation, chemoresistance and apoptosis of cancer cells. Thus, pharmacological formulations encompassing “15-deoxy-delta(12,14)-prostaglandin J2 (PGJ2)  or its analogs” may be used to inhibit cancer progression.

Details of the research findings

Idea Proposed/Formulated (with experimental evidence) by:

Dr L Boominathan Ph.D.

Undisclosed mechanistic information: How 15-deoxy-delta(12,14)-prostaglandin J2 (PGJ2) decreases the expression of Dihydropyrimidine dehydrogenase (DPYD)?

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

Amount: $5

For purchase and payment details, you may reach us at info@genomediscovery.org


References:  

CitationBoominathan, L., Combination therapy for augmenting the anti-cancer drug 5-FU (5-Flurouracil) sensitivity in Human cancers: 15-deoxy-delta(12,14)-prostaglandin J2 (PGJ2) decreases the expression of the rate-limiting enzyme of the ‘uracil catabolic pathway’ Dihydropyrimidine dehydrogenase (DPYD), increases 5-FU accumulation in cancer cells, augments chemosensitivity, and anti-tumor effect via upregulation of its target gene, 24/January/2017, 11.01 pm, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org

Web: http://genomediscovery.org or newbioideas.com/

Courtesy: When you cite drop us a line at info@genomediscovery.org

Comments are closed.